Back

Is left ventricular ejection fraction an effective predictor of ventricular arrhythmias in patients with dilated cardiomyopathy?

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Markers in and of dilated cardiomyopathy Dilated Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mariana Rodrigues Simoes

Coimbra Hospital and University Center, Coimbra (Portugal)

5 More presentations in this session

Presentation thumbnail
Influence of non-sex specific risk factors on the development of a dilated cardiomyopathy in men and women with a titin truncating variant
Ms I. Faassen (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Phenotypic manifestation based on genetics and prevalence of secondary mutations in a sample of patients diagnosed with arrhythmogenic cardiomyopathy
Doctor A. Diaz Exposito (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
Genetic determinants of disease severity in idiopathic dilated cardiomyopathy
Associate Professor J. Lee (Cheongju, KR)
Abstract Slides Video
Presentation thumbnail
Relationship between TTN gene mutation and changes in whole-heart myocardial mechanics in patients with non-ischemic dilated cardiomyopathy: feature-tracking CMR study
Ms G. Jakuskaite (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Biomarkers in action: The role of Procalcitonin, NT-proBNP, and Troponin T in predicting septic cardiomyopathy
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Markers in and of dilated cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Factors related to ventricular arrhythmias in patients with dilated cardiomyopathy hospitalized for acute heart failure
thumbnail
Congress Presentation
What makes hearts race in cardiac implantable electronic device patients?
thumbnail
Congress Presentation
Absence of late gadolinium enhancement and outcomes of cardiac resynchronization therapy in non-ischemic dilated cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources